The latest price target for Immutep (NASDAQ:IMMP) was reported by Baird on June 27, 2024. The analyst firm set a price target for $6.00 expecting IMMP to rise to within 12 months (a possible 198.51% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Immutep (NASDAQ:IMMP) was provided by Baird, and Immutep maintained their outperform rating.

There is no last upgrade for Immutep

There is no last downgrade for Immutep.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immutep, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immutep was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.

While ratings are subjective and will change, the latest Immutep (IMMP) rating was a maintained with a price target of $7.00 to $6.00. The current price Immutep (IMMP) is trading at is $2.01, which is out of the analyst’s predicted range.